miR-199b plays an anticancer role by simultaneously inhibiting the Akt and ERK pathways by directly targeting several components of the Akt and ERK pathways in NSCLC (Fig. 6e). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.